Congshan Sun

Dr. Congshan Sun

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2020 in Experimental Neurology
Verified
Journal Article
Closed access
CSCongshan Sun
Congshan Sun
CSCarlo Serra
Carlo Serra
GLGabsang Lee
Gabsang Lee
KWKathryn R. Wagner
Kathryn R. Wagner

TFTom P. Fleming
Tom P. Fleming
CSCongshan Sun
Congshan Sun
ODOleg Denisenko
Oleg Denisenko
LCLaura Caetano
Laura Caetano
AAAnan R. Aljahdali
Anan R. Aljahdali
PKPooja Khurana
Pooja Khurana
Environment around conception can influence the developmental programme with lasting effects on gestational and postnatal phenotype and with consequences for adult health and disease risk. Peri-conception exposure comprises a crucial part of the ‘Developmental Origins of Health and Disease’ (DOHaD) concept. In this review, we consider the effects of maternal undernutrition experienced during the peri-conception period in select human models and in a mouse experimental model of protein restriction. Human datasets indicate that macronutrient deprivation around conception affect the epigenome, with enduring effects on cardiometabolic and neurological health. The mouse model, comprising maternal low protein diet exclusively during the peri-conception period, has revealed a stepwise progression in altered developmental programming following induction through maternal metabolite deficiency. This progression includes differential effects in extra-embryonic and embryonic cell lineages and tissues, leading to maladaptation in the growth trajectory and increased chronic disease comorbidities. The timeline embraces an array of mechanisms across nutrient sensing and signalling, cellular, metabolic, epigenetic and physiological processes with a coordinating role for mTORC1 signalling proposed. Early embryos appear active participants in environmental sensing to optimise the developmental programme for survival but with the trade-off of later disease. Similar adverse health outcomes may derive from other peri-conception environmental experiences, including maternal overnutrition, micronutrient availability, pollutant exposure and assisted reproductive treatments (ART) and support the need for preconception health before pregnancy.

7 April 2022 in Cell Stem Cell
Verified
Journal Article
Closed access
CSCongshan Sun
Congshan Sun
SKSuraj Kannan
Suraj Kannan
ICIn Young Choi
In Young Choi
HLHoTae Lim
HoTae Lim
HZHao Zhang
Hao Zhang
GLGabsang Lee
Gabsang Lee

4 June 2020 in JCI Insight
Verified
Journal Article
Open access
PDF file
CSCongshan Sun
Congshan Sun
ICIn Young Choi
In Young Choi
YGYazmin I. Rovira Gonzalez
Yazmin I. Rovira Gonzalez
PAPeter Andersen
Peter Andersen
CTC. Conover Talbot
C. Conover Talbot
GLGabsang Lee
Gabsang Lee
Duchenne muscular dystrophy (DMD) is the most common muscular dystrophy. In the present study, when human induced pluripotent stem cells (hiPSCs) were differentiated into myoblasts, the myoblasts derived from DMD patient hiPSCs (DMD hiPSC–derived myoblasts) exhibited an identifiable DMD-relevant phenotype: myogenic fusion deficiency. Based on this model, we developed a DMD hiPSC–derived myoblast screening platform employing a high-content imaging (BD Pathway 855) approach to generate parameters describing morphological as well as myogenic marker protein expression. Following treatment of the cells with 1524 compounds from the Johns Hopkins Clinical Compound Library, compounds that enhanced myogenic fusion of DMD hiPSC–derived myoblasts were identified. The final hits were ginsenoside Rd and fenofibrate. Transcriptional profiling revealed that ginsenoside Rd is functionally related to FLT3 signaling, while fenofibrate is linked to TGF-β signaling. Preclinical tests in mdx mice showed that treatment with these 2 hit compounds can significantly ameliorate some of the skeletal muscle phenotypes caused by dystrophin deficiency, supporting their therapeutic potential. Further study revealed that fenofibrate could inhibit mitochondrion-induced apoptosis in DMD hiPSC–derived cardiomyocytes. We have developed a platform based on DMD hiPSC–derived myoblasts for drug screening and identified 2 promising small molecules with in vivo efficacy.

29 March 2024 in Cells
Verified
Journal Article
Open access
PDF file
CSCongshan Sun
Congshan Sun
CSCarlo Serra
Carlo Serra
BKBrianna Harley Kalicharan
Brianna Harley Kalicharan
JHJeffrey Harding
Jeffrey Harding
MRMahendra Rao
Mahendra Rao
Cell therapies derived from induced pluripotent stem cells (iPSCs) offer a promising avenue in the field of regenerative medicine due to iPSCs’ expandability, immune compatibility, and pluripotent potential. An increasing number of preclinical and clinical trials have been carried out, exploring the application of iPSC-based therapies for challenging diseases, such as muscular dystrophies. The unique syncytial nature of skeletal muscle allows stem/progenitor cells to integrate, forming new myonuclei and restoring the expression of genes affected by myopathies. This characteristic makes genome-editing techniques especially attractive in these therapies. With genetic modification and iPSC lineage specification methodologies, immune-compatible healthy iPSC-derived muscle cells can be manufactured to reverse the progression of muscle diseases or facilitate tissue regeneration. Despite this exciting advancement, much of the development of iPSC-based therapies for muscle diseases and tissue regeneration is limited to academic settings, with no successful clinical translation reported. The unknown differentiation process in vivo, potential tumorigenicity, and epigenetic abnormality of transplanted cells are preventing their clinical application. In this review, we give an overview on preclinical development of iPSC-derived myogenic cell transplantation therapies including processes related to iPSC-derived myogenic cells such as differentiation, scaling-up, delivery, and cGMP compliance. And we discuss the potential challenges of each step of clinical translation. Additionally, preclinical model systems for testing myogenic cells intended for clinical applications are described.